HomeEverolimusEverolimus + Midazolam

Does Everolimus Interact with Midazolam?

Everolimus and Midazolam have a unknown drug interaction according to U.S. FDA drug labeling data. 7.9 Midazolam (CYP3A4/5 Substrate) Single-dose administration of midazolam to healthy volunteers following administration of multiple-dose everolimus indicated that everolimus is a weak inhibitor of CYP3A4/5. Dose adjustment of midazolam or other CYP3A4/5 substrates is not necessary when everolimus is coadministered with midazolam or other CYP3A4/5 substrates [see Clinical Pharmacology ( 12.5 )] . Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Unknown
Everolimus Class
Kinase Inhibitor
Midazolam Class
Benzodiazepine
Management
Consult your pharmacist
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Everolimus and your doctor is considering prescribing Midazolam (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Never stop or change either medication without first consulting your healthcare provider
💊 Everolimus(Everolimus)+💊 Midazolam

Severity & Interaction Details

ℹ️
unknown
Interaction documented — severity unclassified
The FDA label notes an interaction but the severity is not classified in our dataset.
Severity scale
MinorContra
On record
Yes
Drug A class
Kinase Inhibitor
Drug B class
Benzodiazepine
Source
FDA drug label - everolimus

What this means in plain English

7.9 Midazolam (CYP3A4/5 Substrate) Single-dose administration of midazolam to healthy volunteers following administration of multiple-dose everolimus indicated that everolimus is a weak inhibitor of CYP3A4/5. Dose adjustment of midazolam or other CYP3A4/5 substrates is not necessary when everolimus is coadministered with midazolam or other CYP3A4/5 substrates [see Clinical Pharmacology ( 12.5 )] .

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Everolimus and Midazolam against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.